Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis  Mohamad B. Sonbol, Belal Firwana, Talal.

Slides:



Advertisements
Similar presentations
Pascal Rischmann  European Urology Supplements 
Advertisements

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis  Maria I. Carlo, Darren R.
Laparoscopic Versus Open Radical Nephrectomy for Renal Cell Carcinoma: a Systematic Review and Meta-Analysis  Gang Liu, Yulei Ma, Shouhua Wang, Xiancheng.
Dae Keun Kim, Dong Won Park, Koon Ho Rha  European Urology 
Volume 51, Issue 1, Pages (January 2007)
Volume 64, Issue 4, Pages (October 2013)
European Urology Oncology
Volume 68, Issue 1, Pages (July 2015)
Prostate Cancer Epidemic in Sight?
Volume 71, Issue 4, Pages (April 2017)
European Urology Oncology
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 54, Issue 4, Pages (October 2008)
Volume 61, Issue 5, Pages (May 2012)
Volume 52, Issue 5, Pages (November 2007)
Volume 63, Issue 6, Pages (June 2013)
Volume 71, Issue 3, Pages (March 2017)
Volume 70, Issue 3, Pages (September 2016)
Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
Rodolfo Montironi, Ming Zhou, Cristina Magi-Galluzzi, Jonathan I
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic,
European Urology Oncology
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia  Brett Delahunt, John R. Srigley, Lars Egevad,
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
Prostate Cancer Epidemic in Sight?
Volume 50, Issue 3, Pages (September 2006)
Volume 61, Issue 6, Pages (June 2012)
Volume 65, Issue 2, Pages (February 2014)
Stephen B. Williams, Ashish M
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,
Volume 74, Issue 3, Pages (September 2018)
Rectal Injury During Radical Prostatectomy: Focus on Robotic Surgery
Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL,
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 71, Issue 1, Pages (January 2017)
Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
Is Simple Enucleation a Minimal Partial Nephrectomy Responding to the EAU Guidelines’ Recommendations?  Vincenzo Ficarra, Antonio Galfano, Stefano Cavalleri 
Volume 50, Issue 5, Pages (November 2006)
A systematic review and meta-analysis of tests to predict wound healing in diabetic foot  Zhen Wang, PhD, Rim Hasan, MD, Belal Firwana, MD, Tarig Elraiyah,
National Norwegian Practice Patterns for Surgical Treatment of Kidney Cancer Tumors ≤7cm: Adherence to Changes in Guidelines May Improve Overall Survival 
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
Volume 51, Issue 1, Pages (January 2007)
European Urology Oncology
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline  J Noble,
Sergio Bracarda  European Urology Supplements 
European Urology Oncology
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
European Urology is “Your” Journal
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis  Joseph Sargon Joseph, Vincent.
The Cost to Medicare of Bladder Cancer Care
European Urology Oncology
The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy  Neal Patel, Eliza Cricco-Lizza,
Profile of Silodosin European Urology Supplements
European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why?  Jean-Jacques Patard 
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Annika Berntsen, Poul F. Geertsen, Inge Marie Svane  European Urology 
Joaquim Bellmunt  European Urology Supplements 
European Urology Oncology
Jan Roigas  European Urology Supplements 
Pathology and Molecular Pathogenesis of Renal Cell Carcinoma
European Urology Oncology
Volume 51, Issue 5, Pages (May 2007)
Volume 2, Issue 6, Pages (June 2017)
How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?  Shahrokh Shariat, Paolo Gontero, James.
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma  Guillermo de Velasco, Axel Bex, Laurence Albiges, Thomas Powles, Brian.
Presentation transcript:

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis  Mohamad B. Sonbol, Belal Firwana, Talal Hilal, Zhen Wang, Diana Almader-Douglas, Richard W. Joseph, Thai H. Ho  European Urology Oncology  Volume 1, Issue 2, Pages 101-108 (June 2018) DOI: 10.1016/j.euo.2018.03.012 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Meta-analysis of antiangiogenics versus placebo for the overall cohort. VEGFi=VEGF inhibitor. European Urology Oncology 2018 1, 101-108DOI: (10.1016/j.euo.2018.03.012) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Meta-analysis of sunitinib versus placebo for the overall cohort. VEGFi=VEGF inhibitor. European Urology Oncology 2018 1, 101-108DOI: (10.1016/j.euo.2018.03.012) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Meta-analysis of (A) antiangiogenics versus placebo and (B) sunitinib versus placebo for any grade ≥3 AEs, discontinuations due to AEs, and grade 5 AEs (death). AE=adverse event; VEGFi=VEGF inhibitor. European Urology Oncology 2018 1, 101-108DOI: (10.1016/j.euo.2018.03.012) Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018 Copyright © 2018 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.